Use of non-insulin therapies for Type 1 diabetes

Diabetes Technology and Therapeutics

Volumn 15, Issue 11, 2013, Pages 901-908

  Garg, Satish K ^a,b,c   Michels, Aaron W ^a,b   Shah, Viral N ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Diabetes Technology and Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALOGLIPTIN; BROMOCRIPTINE; CANAGLIFLOZIN; COLESEVELAM; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN; LANSOPRAZOLE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; METRELEPTIN; MIGLITOL; OMEPRAZOLE; PANTOPRAZOLE; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; ROSIGLITAZONE; SAXAGLIPTIN; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; VILDAGLIPTIN;

ALOPECIA; ARTERIAL WALL THICKNESS; BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR RISK; COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; CONSTIPATION; COST BENEFIT ANALYSIS; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FATTY ACID OXIDATION; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPERPLASIA; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE MUCOSA; KIDNEY TUBULE ABSORPTION; LACTIC ACIDOSIS; METALLIC TASTE; NAUSEA; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET CELL HYPERPLASIA; PANCREAS SECRETION; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT; URINARY TRACT INFECTION; VASCULAR ENDOTHELIUM; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ALLYLAMINE; ANIMALS; BLOOD GLUCOSE; BROMOCRIPTINE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRINS; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISLET AMYLOID POLYPEPTIDE; LEPTIN; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; UNITED STATES;

EID: 84887125979     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0281     Document Type: Review

References (110)

1. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. 2011. www.cdc.gov/diabetes/ pubs/pdf/ndfs-2011.pdf (accessed August 16, 2013).
2. Switzer SM, Moser EG, Rockler BE, Garg SK: Intensive insulin therapy in patients with type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2012;41:89-104.
3. Atkinson MA, Eisenbarth GS, Michels AW: Type 1 diabetes. Lancet 2013 Jul 25 [Epub ahead of print]. doi:pii: S0140-6736(13)60591-7. 10.1016/S0140-6736(13) 60591-7.
4. Ashiya M, Smith RET: Non-insulin therapies for type 2 diabetes. Nat Rev Drug Discov 2007;6:777-778.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
6. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
7. Sehra D, Sehra S, Sehra ST: Sulfonylureas: do we need to introspect safety again Expert Opin Drug Saf 2011;10: 851-861.
8. Pernet A, Trimble ER, Kuntschen F, Assal JP, Hahn C, Renold AE: Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo. J Clin Endocrinol Metab 1985;61:247-251.
9. Keller U, Mü ller R, Berger W: Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects. Horm Metab Res 1986;18:599-603.
10. Garrel DR, Picq R, Bajard L, Harfouche M, Tourniaire J: Acute effect of glyburide on insulin sensitivity in type I diabetic patients. J Clin Endocrinol Metab 1987;65: 896-900.
11. Simonson DC, Delprato S, Castellino P, Groop L, DeFronzo RA: Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients. Diabetes 1987;36:136-146.
12. Schimmack G, Defronzo RA, Musi N: AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 2006;8:591-602.
13. El Messaoudi S, Rongen GA, Riksen NP: Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep 2013;15:314.
14. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A: Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013;8:e71583.
15. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR: The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010;53:809-820.
16. REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL). Identifier NCT01483560. http://clinicaltrials.gov/show/NCT01483560 (accessed September 13, 2013).
17. Yki-Jä rvinen H: Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
18. Faillie JL, Petit P, Montastruc JL, Hillaire-Buys D: Scientific evidence and controversies about pioglitazone and bladder cancer: which lessons can be drawn Drug Saf 2013 Jul 20 [Epub ahead of print]. doi: 10.1007/s40264-013-0086- y.
19. Kawano Y, Irie J, Nakatani H, Yamada S: Pioglitazone might prevent the progression of slowly progressive type 1 diabetes. Intern Med 2009;48:1037-1039.
20. Bhat R, Bhansali A, Bhadada S, Sialy R: Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract 2007;78:349-354.
21. Shimada A, Shigihara T, Okubo Y, Katsuki T, Yamada Y, Oikawa Y: Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev 2011;27:951-953.
22. Shigihara T, Okubo Y, Kanazawa Y, Oikawa Y, Shimada A: Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes. Ann N Y Acad Sci 2006;1079:365-368.
23. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C: Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154-163.
24. Neuser D, Benson A, Brü ckner A, Goldberg RB, Hoogwerf BJ, Petzinna D: Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig 2005;25:579-587.
25. Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, Panelo AA, Kim DK, Embong M: An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 1998;21:1058-1061.
26. Dash S, Crisp S, Hartnell S, Donald S, Davenport K, Simmons D, Evans M: Successful use of acarbose to manage post-prandial glycaemia in two patients with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2012;95:e49-e51.
27. Juntti-Berggren L, Pigon J, Hellström P, Holst JJ, Efendic S: Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes. Diabetes Nutr Metab 2000; 13:7-12.
28. Rabasa-Lhoret R, Burelle Y, Ducros F, Bourque J, Lavoie C, Massicotte D, Péronnet F, Chiasson JL: Use of an alphaglucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated type 1 diabetic subjects. Diabet Med 2001;18:739-744.
29. Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, Ochi F, Kusunoki Y, Tokuda M, Murai K, Hamaguchi T, Namba M: Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J 2011;58:869-877.
30. Bayliss WM, Starling EH: The mechanism of pancreatic secretion. J Physiol 1902;28:325-353.
31. La Barre J: Sur les possibilités d'un traitement du diabète par l'incrétine. Bull Acad R Med Belg 1932;12:620-634.
32. Yalow RS, Berson SA: Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960;39:1157-1175.
33. Elrick H, Stimmler L, Hlad CJ, Arai Y: Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-1082.
34. Food and Drug Administration: http://www.accessdata .fda.gov/drugsatfda- docs/nda/2007/022044TOC.cfm (accessed August 30, 2013).
35. Food and Drug Administration: http://www.accessdata .fda.gov/drugsatfda- docs/nda/2011/201280Orig1s000TOC .cfm (accessed August 30, 2013).
36. Food and Drug Administration: http://www.accessdata .fda.gov/drugsatfda- docs/nda/2009/022350s000TOC.cfm (accessed August 30, 2013).
37. Food and Drug Administration: http://www.accessdata .fda.gov/drugsatfda- docs/nda/2009/021919-byetta-toc .cfm (accessed August 30, 2013).
38. Food and Drug Administration: http://www.accessdata .fda.gov/drugsatfda- docs/nda/2010/022341s000TOC.cfm (accessed August 30, 2013).
39. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB: The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283: E745-E752.
40. Rutti S, Sauter NS, Bouzakri K, Prazak R, Halban PA, Donath MY: In vitro proliferation of adult human betacells. PLoS One 2012;7:e35801.
41. Hare KJ, Vilsbøll T, Holst JJ, Knop FK: Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 2010;298:E832-E837.
42. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type 1 diabetic patients. Diabetes Care 1996;19:580-586.
43. Ghazi T, Rink L, Sherr JL, Herold KC: Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and IV glucose challenges. Diabetes Care 2013 August 12 [Epub ahead of print]. doi: 10.2337/dc13-1169.
44. Kielgast U, Asmar M, Madsbad S, Holst JJ: Effect of glucagon-like peptide-1 on alpha-and beta-cell function in Cpeptide-negative type 1 diabetic patients. J Clin Endocrinol Metab 2010;95:2492-2496.
45. Kielgast U, Krarup T, Holst JJ, Madsbad S: Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual b-cell function. Diabetes Care 2011;34: 1463-1468.
46. Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P: Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011; 165:77-84.
47. Hari Kumar KV, Shaikh A, Prusty P: Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract 2013;100:e55-e58.
48. Rother KI, Spain LM, Wesley RA, Digon BJ 3rd, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM: Effects of exenatide alone and in combination with daclizumab on beta-cell function in longstanding type 1 diabetes. Diabetes Care 2009;32:2251-2257.
49. Pettus J, Hirsch I, Edelman S: GLP-1 agonists in type 1 diabetes. Clin Immunol 2013 April 17 [Epub ahead of print]. pii: S1521-6616(13)00097-1. doi: 10.1016/j.clim.2013 .04.006.
50. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK: Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011;28:1176-1181.
51. Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK: Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebocontrolled trial. Endocr Pract 2013;19:19-28.
52. Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E: Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug Des Dev Ther 2013;7:99-104.
53. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ: Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013;12:3.
54. Monami M, Dicembrini I, Martelli D, Mannucci E: Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27:57-64.
55. Sun F, Yu K, Wu S, Zhang Y, Yang Z, Shi L, Ji L, Zhan S: Cardiovascular safety and glycemic control of glucagonlike peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract 2012;98:386-395.
56. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mozenson O, McGuire DK, Ray KK, Leiter LA, Raz I; the SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013 Sep 2 [Epub ahead of print]. doi: 10.1056/NEJMoa1307684.
57. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; the EXAMINE Investigators: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 Sep 2. [Epub ahead of print]. doi: 10.1056/NEJMoa1305889.
58. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation (LEADER). Identifier NCT01179048. http://clinicaltrials.gov/ct2/show/NCT01179048 (accessed September 13, 2013).
59. Sitagliptin Cardiovascular Outcome Study (0431-082 AM1) (TECOS). Identifier NCT00790205. http://clinicaltrials.gov/ct2/show/NCT00790205 (accessed September 13, 2013).
60. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes. Identifier NCT01243424. http://clinicaltrials. gov/ct2/show/NCT01243424 (accessed September 13, 2013).
61. Ahmad SR, Swann J: Exenatide and rare adverse events. N Engl J Med 2008;358:1970-1971.
62. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC: Pancreatitis, pancreatic, and thyroid cancer with glucagonlike peptide-1-based therapies. Gastroenterology 2011;141: 150-156.
63. Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R: Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire Diabetologia 2010;53:1-6.
64. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB: Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-539.
65. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC: Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62:2595-2604.
66. Harja E, Lord J, Skyler JS: An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technol Ther 2013;15:609-618.
67. Kahn SE: Incretin therapy and islet pathology-a time for caution. Diabetes 2013;62:2178-2180.
68. Mogensen CE: Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28:101-109.
69. Mather A, Pollock C: Glucose handling by the kidney. Kidney Int Suppl 2011;(120):S1-S6.
70. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14.
71. Elkinson S, Scott LJ: Canagliflozin: first global approval. Drugs 2013;73:979-988.
72. Abdul-Ghani MA, Defronzo RA: Dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2013;14:1695-1703.
73. Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers. Identifier NCT00836225. http://clinicaltrials.gov/ct2/ show/NCT00836225 (accessed September 13, 2013).
74. Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks. Identifier NCT00297180. http://clinicaltrials.gov/ct2/ show/NCT00297180 (accessed September 13, 2013).
75. An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes. Identifier NCT01022112. http://clinicaltrials.gov/ct2/show/ NCT01022112 (accessed September 13, 2013).
76. Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus. Identifier NCT01029704. http://clinicaltrials.gov/ct2/show/NCT01029704 (accessed September 13, 2013).
77. A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus. Identifier NCT00963768. http://clinical trials.gov/ct2/show/NCT00963768 (accessed September 13, 2013).
78. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A: Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-274.
79. Burki TK: FDA rejects novel diabetes drug over safety fears. Lancet 2012;379:507.
80. Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR: LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012;92:158-169.
81. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM: Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-1729.
82. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, Isaji M: Sergliflozinetabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609:148-154.
83. Luippold G, Klein T, Mark M, Grempler R: Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012;14:601-607.
84. Adeghate E, Kalász H: Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med Chem J 2011;5:78-81.
85. Ryan GJ, Jobe LJ, Martin R: Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2005;27:1500-1512.
86. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, Maggs D, Kolterman OG: Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med 2013;125:136-144.
87. Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C: Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes 2005;113:199-204.
88. Weinzimer SA, Sherr JL, Cengiz E, Kim G, Ruiz JL, Carria L, Voskanyan G, Roy A, Tamborlane WV: Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012; 35:1994-1999.
89. Holt RI, Barnett AH, Bailey CJ: Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab 2010;12:1048-1057.
90. Kalra S, Kalra B, Agrawal N, Kumar S: Dopamine: the forgotten felon in type 2 diabetes. Recent Pat Endocr Metab Immune Drug Discov 2011;5:61-65.
91. Defronzo RA: Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011;34:789-794.
92. Ooi CP, Loke SC: Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012;12:CD009361.
93. Garg SK, Ritchie PJ, Moser EG, Snell-Bergeon JK, Freson BJ, Hazenfield RM: Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab 2011;13: 137-143.
94. Amitani M, Asakawa A, Amitani H, Inui A: The role of leptin in the control of insulin-glucose axis. Front Neurosci 2013;7:51.
95. Chou K, Perry CM: Metreleptin: first global approval. Drugs 2013;73:989-997.
96. Trevaskis JL, Parkes DG, Roth JD: Insights into amylin-leptin synergy. Trends Endocrinol Metab 2010;21:473-479.
97. Effects of Metreleptin in Type 1 Diabetes Mellitus. Identifier NCT01268644. http://clinicaltrials.gov/show/NCT01268644 (accessed August 29, 2013).
98. Cowey SL, Quast M, Belalcazar LM, Wei J, Deng X, Given R, Singh P: Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression. Cancer 2005;103:2643-2653.
99. Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC: Increased islet b cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 2006;49:2689-2696.
100. Hove KD, Færch K, Bödvarsdó ttir TB, Karlsen AE, Petersen JS, Vaag A: Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients-a retrospective analysis. Diabetes Res Clin Pract 2010;90: e72-e74.
101. Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R: Are proton pump inhibitors a new antidiabetic drug A cross sectional study. World J Diabetes 2011;2:217-220.
102. Singh PK, Hota D, Dutta P, Sachdeva N, Chakrabarti A, Srinivasan A, Singh I, Bhansali A: Pantoprazole improves glycemic control in type 2 diabetes: a randomized, doubleblind, placebo-controlled trial. J Clin Endocrinol Metab 2012;97:E2105-E2108.
103. Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes (REPAIR-T1D). Identifier NCT01155284. http://clinicaltrials.gov/ct2/show/NCT01155284 (accessed August 30, 2013).
104. Garg SK: Impact of insulin delivery devices in diabetes care. Diabetes Technol Ther 2010;12(Suppl 1):S-1-S-4.
105. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. The DCCT Research Group. Am J Med 1991;90:450-459.
106. Garg SK, Moser E: How basal insulin analogs have changed diabetes care. Diabetes Technol Ther 2011;13 (Suppl 1):S-1-S-4.
107. Moser E, Morris A, Garg S: Emerging diabetes technologies. Diabetes Res Clin Pract 2012;97:16-26.
108. Bhide, Grey JMS, Moser EG, Garg SK: A primary care perspective on the use of continuous glucose monitoring in clinical practice. Diabetes Technol Ther 2013;15:533-537.
109. Moser EG, Crew LB, Garg SK: Role of continuous glucose monitoring in diabetes management. Avances en Diabetologia 2010;26:73-79.
110. Blevins TC, Bode BW, Garg SK, Grunberger G, Hirsch IB, Jovanovic L, Nardacci E, Orzeck EA, Roberts VL, Tamborlane WV; AACE Continuous Glucose Monitoring Task Force: Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring. Endocr Pract 2010;16:730-745.